Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 390

1.

Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy.

Sakamoto S, Inoue H, Kaneko MK, Ogasawara S, Kajikawa M, Urano S, Ohba SI, Kato Y, Kawada M.

Cancer Sci. 2019 Sep 11. doi: 10.1111/cas.14196. [Epub ahead of print]

2.

Visible-light driven hydrogen production using chlorophyll derivatives conjugated with a viologen moiety in the presence of platinum nanoparticles.

Ikeyama S, Hizume S, Takahashi T, Ogasawara S, Amao Y, Tamiaki H.

Photochem Photobiol Sci. 2019 Sep 4. doi: 10.1039/c9pp00176j. [Epub ahead of print]

PMID:
31482917
3.

Programmed death-ligand 1 expression is an unfavorable prognostic factor of hepatocellular carcinoma after archiving sustained virologic response for hepatitis C virus infection.

Kondo R, Akiba J, Ogasawara S, Nakashima O, Naito Y, Kusano H, Mihara Y, Tanigawa M, Yano H.

Oncol Lett. 2019 Aug;18(2):1458-1466. doi: 10.3892/ol.2019.10448. Epub 2019 Jun 7.

4.

KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells.

Okamoto K, Tanaka Y, Ogasawara S, Obuse C, Nakayama JI, Yano H, Tsuneoka M.

Oncotarget. 2019 Jul 30;10(46):4743-4760. doi: 10.18632/oncotarget.27092. eCollection 2019 Jul 30.

5.

Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study.

Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F.

BMC Cancer. 2019 Aug 13;19(1):795. doi: 10.1186/s12885-019-5989-2.

6.

DzMab-1: Anti-Human Diacylglycerol Kinaseζ Monoclonal Antibody for Immunocytochemistry.

Nakano T, Ogasawara S, Tanaka T, Hozumi Y, Sano M, Sayama Y, Yamada S, Kaneko MK, Kato Y, Goto K.

Monoclon Antib Immunodiagn Immunother. 2019 Aug;38(4):179-182. doi: 10.1089/mab.2019.0024.

PMID:
31403910
7.

Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.

Ogasawara S, Ooka Y, Itokawa N, Inoue M, Okabe S, Seki A, Haga Y, Obu M, Atsukawa M, Itobayashi E, Mizumoto H, Sugiura N, Azemoto R, Kanayama K, Kanzaki H, Maruta S, Maeda T, Kusakabe Y, Yokoyama M, Kobayashi K, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N.

Invest New Drugs. 2019 Jun 6. doi: 10.1007/s10637-019-00801-8. [Epub ahead of print]

PMID:
31172442
8.

Malic enzyme 1 is a potential marker of combined hepatocellular cholangiocarcinoma, subtype with stem-cell features, intermediate-cell type.

Mihara Y, Akiba J, Ogasawara S, Kondo R, Fukushima H, Itadani H, Obara H, Kakuma T, Kusano H, Naito Y, Okuda K, Nakashima O, Yano H.

Hepatol Res. 2019 May 11. doi: 10.1111/hepr.13365. [Epub ahead of print]

PMID:
31077496
9.

Genome-Wide Mapping of Bivalent Histone Modifications in Hepatic Stem/Progenitor Cells.

Kanayama K, Chiba T, Oshima M, Kanzaki H, Koide S, Saraya A, Miyagi S, Mimura N, Kusakabe Y, Saito T, Ogasawara S, Suzuki E, Ooka Y, Maruyama H, Iwama A, Kato N.

Stem Cells Int. 2019 Apr 1;2019:9789240. doi: 10.1155/2019/9789240. eCollection 2019.

10.

Expression and role of regulator of G-protein signaling 5 in squamous cell carcinoma of the tongue.

Abe Y, Ogasawara S, Akiba J, Naito Y, Kondo R, Nakamura K, Kusukawa J, Yano H.

Clin Exp Dent Res. 2019 Mar 4;5(2):160-169. doi: 10.1002/cre2.166. eCollection 2019 Apr.

11.

C31-Selective substitution of cationic N-heteroaromatic groups into a 3-vinylated chlorophyll-a derivative.

Takahashi T, Ogasawara S, Echizen S, Shinozaki Y, Tamiaki H.

Org Biomol Chem. 2019 Jun 5;17(22):5490-5495. doi: 10.1039/c9ob00130a.

PMID:
30869105
12.

GLCCI1 is a novel protector against glucocorticoid-induced apoptosis in T cells.

Kiuchi Z, Nishibori Y, Kutsuna S, Kotani M, Hada I, Kimura T, Fukutomi T, Fukuhara D, Ito-Nitta N, Kudo A, Takata T, Ishigaki Y, Tomosugi N, Tanaka H, Matsushima S, Ogasawara S, Hirayama Y, Takematsu H, Yan K.

FASEB J. 2019 Jun;33(6):7387-7402. doi: 10.1096/fj.201800344RR. Epub 2019 Mar 12.

PMID:
30860871
13.

Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.

Kurose H, Ueda K, Kondo R, Ogasawara S, Kusano H, Sanada S, Naito Y, Akiba J, Kakuma T, Igawa T, Yano H.

Anticancer Res. 2019 Feb;39(2):957-964. doi: 10.21873/anticanres.13199.

PMID:
30711981
14.

High sulfite oxidase expression could predict postoperative biochemical recurrence in patients with prostate cancer.

Kurose H, Naito Y, Akiba J, Kondo R, Ogasawara S, Kusano H, Sanada S, Abe H, Kakuma T, Ueda K, Igawa T, Yano H.

Med Mol Morphol. 2019 Sep;52(3):164-172. doi: 10.1007/s00795-018-00214-1. Epub 2019 Jan 10.

PMID:
30631948
15.

[Regorafenib in patients with advanced hepatocellular carcinoma;current status and future perspective].

Ogasawara S, Ooka Y, Kato N.

Nihon Shokakibyo Gakkai Zasshi. 2019;116(1):28-35. doi: 10.11405/nisshoshi.116.28. Japanese. No abstract available.

PMID:
30626851
16.

Phytoavailability of 137Cs and stable Cs in soils from different parent materials in Fukushima, Japan.

Ogasawara S, Eguchi T, Nakao A, Fujimura S, Takahashi Y, Matsunami H, Tsukada H, Yanai J, Shinano T.

J Environ Radioact. 2019 Mar;198:117-125. doi: 10.1016/j.jenvrad.2018.12.028. Epub 2018 Dec 31.

PMID:
30605858
17.

Inhibition of protein phosphatase PPM1D enhances retinoic acid-induced differentiation in human embryonic carcinoma cell line.

Ogasawara S, Chuman Y, Michiba T, Kamada R, Imagawa T, Sakaguchi K.

J Biochem. 2019 Jun 1;165(6):471-477. doi: 10.1093/jb/mvy119.

PMID:
30576481
18.

Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients.

Kumagai J, Taida T, Ogasawara S, Nakagawa T, Iino Y, Shingyoji A, Ishikawa K, Akizue N, Yamato M, Takahashi K, Ohta Y, Hamanaka S, Okimoto K, Nakamura M, Ohyama H, Saito K, Kusakabe Y, Maruoka D, Yasui S, Matsumura T, Sugiyama H, Sakai Y, Mikata R, Arai M, Katsuno T, Tsuyuguchi T, Kato N.

PLoS One. 2018 Dec 20;13(12):e0209352. doi: 10.1371/journal.pone.0209352. eCollection 2018.

19.

DgMab-6: Antihuman DGKγ Monoclonal Antibody for Immunocytochemistry.

Nakano T, Ogasawara S, Tanaka T, Hozumi Y, Yamaki A, Sakane F, Shirai Y, Nakamura T, Yanaka M, Yamada S, Kaneko MK, Kato Y, Goto K.

Monoclon Antib Immunodiagn Immunother. 2018 Nov;37(5):229-232. doi: 10.1089/mab.2018.0026.

PMID:
30362931
20.

Detection of Tiger Podoplanin Using the Anti-Cat Podoplanin Monoclonal Antibody PMab-52.

Yamada S, Itai S, Furusawa Y, Sano M, Nakamura T, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Fukui M, Harada H, Mizuno T, Sakai Y, Ogasawara S, Murata T, Uchida H, Tahara H, Kaneko MK, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2018 Nov;37(5):224-228. doi: 10.1089/mab.2018.0033.

PMID:
30362928
21.

Transcription Driven by Reversible Photocontrol of Hyperstable G-Quadruplexes.

Ogasawara S.

ACS Synth Biol. 2018 Nov 16;7(11):2507-2513. doi: 10.1021/acssynbio.8b00216. Epub 2018 Oct 17.

PMID:
30350586
22.

Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.

Ooka Y, Miho K, Shuntaro O, Nakamura M, Ogasawara S, Suzuki E, Yasui S, Chiba T, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N, Mochizuki H, Omata M.

Hepatol Int. 2018 Nov;12(6):523-530. doi: 10.1007/s12072-018-9895-5. Epub 2018 Sep 21.

PMID:
30242733
23.

Effects of Neuromuscular Electrical Stimulation of the Quadriceps and Diaphragm in Critically Ill Patients: A Pilot Study.

Leite MA, Osaku EF, Albert J, Costa CRLM, Garcia AM, Czapiesvski FDN, Ogasawara SM, Bertolini GRF, Jorge AC, Duarte PAD.

Crit Care Res Pract. 2018 Jul 8;2018:4298583. doi: 10.1155/2018/4298583. eCollection 2018.

24.

Novel Mechanism of Fatty Acid Sensing in Enteroendocrine Cells: Specific Structures in Oxo-Fatty Acids Produced by Gut Bacteria Are Responsible for CCK Secretion in STC-1 Cells via GPR40.

Hira T, Ogasawara S, Yahagi A, Kamachi M, Li J, Nishimura S, Sakaino M, Yamashita T, Kishino S, Ogawa J, Hara H.

Mol Nutr Food Res. 2018 Oct;62(19):e1800146. doi: 10.1002/mnfr.201800146. Epub 2018 Jul 25.

PMID:
29938900
25.

Correspondence.

Ogasawara S, Chiba T, Ooka Y, Yokosuka O, Kato N.

Hepatology. 2018 Sep;68(3):1207-1208. doi: 10.1002/hep.30110. No abstract available.

PMID:
29901217
26.

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators.

Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018 Sep;19(9):e440.

PMID:
29875066
27.

Left gastric vein-based noninvasive test for esophageal varices: a same-day comparison of portal hemodynamic assessment with endoscopic appearance.

Maruyama H, Kobayashi K, Kiyono S, Ogasawara S, Ooka Y, Suzuki E, Chiba T, Kato N.

Clin Transl Gastroenterol. 2018 May 25;9(5):154. doi: 10.1038/s41424-018-0021-8.

28.

Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma.

Ishikawa K, Chiba T, Ooka Y, Suzuki E, Ogasawara S, Maeda T, Yokoyama M, Inoue M, Wakamatsu T, Kusakabe Y, Saito T, Tawada A, Arai M, Kanda T, Maruyama H, Imazeki F, Kato N.

Oncotarget. 2018 Apr 20;9(30):21560-21568. doi: 10.18632/oncotarget.25108. eCollection 2018 Apr 20.

29.

Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.

Masui K, Komori T, Kato Y, Masutomi K, Ichimura K, Ogasawara S, Kaneko MK, Oki H, Suzuki H, Nitta M, Maruyama T, Muragaki Y, Kawamata T, Sawada T, Shibata N.

Biomed Res Int. 2018 Mar 5;2018:7945845. doi: 10.1155/2018/7945845. eCollection 2018.

30.

Hepatocellular carcinoma after direct-acting antiviral agents: Can liver stiffness kinetics help identify patients at lower risk?

Rigamonti C, Ogasawara S.

Dig Liver Dis. 2018 Jun;50(6):580-582. doi: 10.1016/j.dld.2018.03.025. Epub 2018 Mar 28. No abstract available.

PMID:
29678415
31.

Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.

Piscaglia F, Ogasawara S.

Liver Cancer. 2018 Mar;7(1):104-119. doi: 10.1159/000485471. Epub 2018 Jan 12. Review.

32.

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events.

Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Moriyama M, Kato N.

Oncotarget. 2018 Mar 23;9(22):16263-16270. doi: 10.18632/oncotarget.24620. eCollection 2018 Mar 23.

33.

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.

PMID:
29631810
34.

Epitope Mapping of Monoclonal Antibody PMab-48 Against Dog Podoplanin.

Yamada S, Kaneko MK, Itai S, Chang YW, Nakamura T, Yanaka M, Ogasawara S, Murata T, Uchida H, Tahara H, Harada H, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2018 Jun;37(3):162-165. doi: 10.1089/mab.2018.0006. Epub 2018 Apr 2.

PMID:
29608407
35.

Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N.

Oncotarget. 2018 Feb 3;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20.

36.

Regulator of G-protein signaling 5 enhances portal vein invasion in hepatocellular carcinoma.

Umeno Y, Ogasawara S, Akiba J, Hattori S, Kusano H, Nakashima O, Koga H, Torimura T, Yamakawa R, Yano H.

Oncol Lett. 2018 Feb;15(2):1763-1770. doi: 10.3892/ol.2017.7474. Epub 2017 Nov 23.

37.

SUOX is negatively associated with multistep carcinogenesis and proliferation in oral squamous cell carcinoma.

Nakamura K, Akiba J, Ogasawara S, Naito Y, Nakayama M, Abe Y, Kusukawa J, Yano H.

Med Mol Morphol. 2018 Jun;51(2):102-110. doi: 10.1007/s00795-017-0177-4. Epub 2017 Dec 26.

PMID:
29280012
38.

A spontaneously immortalized Schwann cell line from aldose reductase-deficient mice as a useful tool for studying polyol pathway and aldehyde metabolism.

Niimi N, Yako H, Takaku S, Kato H, Matsumoto T, Nishito Y, Watabe K, Ogasawara S, Mizukami H, Yagihashi S, Chung SK, Sango K.

J Neurochem. 2018 Mar;144(6):710-722. doi: 10.1111/jnc.14277. Epub 2018 Jan 16.

39.

Generation of Conformation-Specific Antibody Fragments for Crystallization of the Multidrug Resistance Transporter MdfA.

Jaenecke F, Nakada-Nakura Y, Nagarathinam K, Ogasawara S, Liu K, Hotta Y, Iwata S, Nomura N, Tanabe M.

Methods Mol Biol. 2018;1700:97-109. doi: 10.1007/978-1-4939-7454-2_7.

PMID:
29177828
40.

Cathepsin K activity controls cardiotoxin-induced skeletal muscle repair in mice.

Ogasawara S, Cheng XW, Inoue A, Hu L, Piao L, Yu C, Goto H, Xu W, Zhao G, Lei Y, Yang G, Kimura K, Umegaki H, Shi GP, Kuzuya M.

J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):160-175. doi: 10.1002/jcsm.12248. Epub 2017 Oct 23.

41.

Brainstem infarction associated with HHV-6 infection in an infant.

Wada A, Muramatsu K, Sunaga Y, Mizuno T, Takei M, Ogasawara S, Uchida M, Tsukida K, Tashiro M.

Brain Dev. 2018 Mar;40(3):242-246. doi: 10.1016/j.braindev.2017.09.005. Epub 2017 Sep 25.

PMID:
28958731
42.

Henoch-Schönlein Purpura Complicated by Hepatocellular Carcinoma.

Akizue N, Suzuki E, Yokoyama M, Inoue M, Wakamatsu T, Saito T, Kusakabe Y, Ogasawara S, Ooka Y, Tawada A, Maru Y, Matsue H, Chiba T.

Intern Med. 2017 Nov 15;56(22):3041-3045. doi: 10.2169/internalmedicine.8885-17. Epub 2017 Sep 25.

43.

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.

Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Saito T, Kobayashi K, Kiyono S, Nakamura M, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N.

Invest New Drugs. 2018 Apr;36(2):332-339. doi: 10.1007/s10637-017-0507-3. Epub 2017 Sep 11.

PMID:
28891038
44.

Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis.

Maruyama H, Kobayashi K, Kiyono S, Ogasawara S, Suzuki E, Ooka Y, Chiba T, Yamaguchi T.

Int J Med Sci. 2017 Jul 19;14(9):804-810. doi: 10.7150/ijms.19847. eCollection 2017.

45.

Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis.

Kobayashi K, Maruyama H, Kiyono S, Ogasawara S, Suzuki E, Ooka Y, Chiba T, Kato N, Yamaguchi T.

J Gastroenterol. 2018 May;53(5):652-659. doi: 10.1007/s00535-017-1378-2. Epub 2017 Aug 18.

PMID:
28821966
46.

Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line.

Ogasawara S, Nakayama M, Akiba J, Kusano H, Yano H.

Oncol Lett. 2017 Aug;14(2):2170-2176. doi: 10.3892/ol.2017.6451. Epub 2017 Jun 21.

47.

A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization.

Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Nagai K, Nakagawa T, Sugawara T, Hanaoka H, Kanai F, Yokosuka O.

Hepatology. 2018 Feb;67(2):575-585. doi: 10.1002/hep.29403. Epub 2017 Dec 23.

PMID:
28746788
48.

DaMab-2: Anti-Human DGKα Monoclonal Antibody for Immunocytochemistry.

Nakano T, Ogasawara S, Tanaka T, Hozumi Y, Mizuno S, Satoh E, Sakane F, Okada N, Taketomi A, Honma R, Nakamura T, Saidoh N, Yanaka M, Itai S, Handa S, Chang YW, Yamada S, Kaneko MK, Kato Y, Goto K.

Monoclon Antib Immunodiagn Immunother. 2017 Aug;36(4):181-184. doi: 10.1089/mab.2017.0023. Epub 2017 Jul 25.

PMID:
28742439
49.

Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress.

Yang G, Lei Y, Inoue A, Piao L, Hu L, Jiang H, Sasaki T, Wu H, Xu W, Yu C, Zhao G, Ogasawara S, Okumura K, Kuzuya M, Cheng XW.

Atherosclerosis. 2017 Sep;264:1-10. doi: 10.1016/j.atherosclerosis.2017.07.014. Epub 2017 Jul 13.

PMID:
28734203
50.

Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.

Kaneko MK, Kunita A, Yamada S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Ogasawara S, Ohishi T, Abe S, Itai S, Harada H, Kawada M, Nishioka Y, Fukayama M, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2017 Aug;36(4):157-162. doi: 10.1089/mab.2017.0020. Epub 2017 Jun 30.

PMID:
28665782

Supplemental Content

Loading ...
Support Center